Actinium Pharmaceuticals (Delaware) (ATNM) vs Cel-Sci (CVM)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Actinium Pharmaceuticals (Delaware) (ATNM) has outperformed Cel-Sci (CVM) over the past year, losing 29.9% versus a loss of 80.6%. Over five years, ATNM leads with a -86.6% price change compared with -99.4% for CVM. Actinium Pharmaceuticals (Delaware) is the larger company by market cap ($34.3 million vs $33.2 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ATNM | CVM |
|---|---|---|
| Share price | $1.09 | $1.89 |
| Market cap | $34.27M | $33.24M |
| 1-day change | +0.93% | -3.08% |
| YTD return | -20.59% | -62.93% |
| 1-year return | -29.87% | -80.56% |
| 5-year return | -86.57% | -99.38% |
| P/E ratio (TTM) | 3.03 | — |
| EPS (TTM) | $0.36 | $-1.69 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $1.74 | $10.24 |
| 52-week low | $0.735 | $0.89 |
| Distance from 52-week high | -37.36% | -81.54% |
| Analyst consensus | none | none |
| Avg. price target upside | +230.28% | +561.38% |
| Average volume | 139.78K | 243.94K |
| Shares outstanding | 31.44M | 17.59M |
| Employees | 27 | — |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ATNM has outperformed CVM by 50.7 percentage points over the past year.
About Actinium Pharmaceuticals (Delaware)
ATNM stock →Actinium Pharmaceuticals, Inc. develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies.
Health Care · Biotechnology: Pharmaceutical Preparations · 27 employees
About Cel-Sci
CVM stock →CEL-SCI Corporation, a clinical-stage biotechnology company, engages in the research and development to treat cancer and other diseases by using the immune system in the United States. The company's lead immunotherapy is Multikine, which has completed Phase III clinical trials for the potential treatment of certain head and neck cancers.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances)
ATNM vs CVM FAQ
Which is bigger, Actinium Pharmaceuticals (Delaware) or Cel-Sci?
Actinium Pharmaceuticals (Delaware) (ATNM) is larger, with a market capitalization of $34.27M compared with $33.24M for Cel-Sci (CVM).
Which stock has performed better over the past year, ATNM or CVM?
ATNM returned -29.87% over the past 12 months, compared with -80.56% for CVM (price return, excluding dividends). Past performance does not predict future results.
Are Actinium Pharmaceuticals (Delaware) and Cel-Sci in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Pharmaceutical Preparations for Actinium Pharmaceuticals (Delaware) and Biotechnology: Biological Products (No Diagnostic Substances) for Cel-Sci.